Core Insights - HUTCHMED will host a Research & Development update on October 31, 2025, in Shanghai and via webcast [1][2] Group 1: Event Details - The event will feature Dr. Michael Shi, who will discuss the company's R&D strategy, including the Antibody Targeted Therapy Conjugates platform and updates on late-stage pipeline development [2] - The in-person event will take place from 3:00 p.m. to 5:00 p.m. HKT and will be conducted in Chinese, with a live English webcast at 8:00 p.m. HKT [3] - Both webcasts will be available live on the company website, with a replay accessible shortly after the event [4] Group 2: Company Overview - HUTCHMED is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases [5] - The company has successfully marketed its first three medicines in China, with the first also approved globally, including in the US, Europe, and Japan [5]